- Patients
- Clinical Research
- Find a clinical trial
- CA224-1093
Lung
CA224-1093
A Phase 3, Randomized, open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%
Trial overview
Medical Oncology
Non-small cell lung cancer (NSCLC)
Lung & bronchus
III
Registration number: NCT06561386
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
Clinical trials enquiries
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.